Calciphylaxis

Summary

Calciphylaxis (MONDO:0017215) is a disease and 20 clinical trials. Top therapeutic interventions include sodium thiosulfate, lanthanum carbonate, and magnesium citrate. A subtype of calcinosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 13
• Clinical trials: 20

Clinical features

Signs & symptoms

Clinical features (HPO)

13 HPO clinical features (Orphanet curated; top 13 by frequency):

HPO ID	Term	Frequency
HP:0000867	Secondary hyperparathyroidism	Very frequent (80-99%)
HP:0000965	Cutis marmorata	Very frequent (80-99%)
HP:0001939	Abnormality of metabolism/homeostasis	Very frequent (80-99%)
HP:0002905	Hyperphosphatemia	Very frequent (80-99%)
HP:0003207	Arterial calcification	Very frequent (80-99%)
HP:0003774	Stage 5 chronic kidney disease	Very frequent (80-99%)
HP:0011122	Abnormality of skin physiology	Very frequent (80-99%)
HP:0011986	Ectopic ossification	Very frequent (80-99%)
HP:0100658	Cellulitis	Very frequent (80-99%)
HP:0100758	Gangrene	Very frequent (80-99%)
HP:0100806	Sepsis	Very frequent (80-99%)
HP:0200042	Skin ulcer	Very frequent (80-99%)
HP:0033260	Livedo racemosa	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	calciphylaxis
Mondo ID	MONDO:0017215
MeSH	D002115
Orphanet	280062
DOID	DOID:4734
ICD-11	574291789
NCIT	C84607
SNOMED CT	237900002
UMLS	C0006666
MedGen	2404
GARD	0005980
MedDRA	10051714
Is cancer (heuristic)	no

Also known as: idiopathic calciphylaxis

Disease family

This is a subtype of calcinosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › mineral metabolism disease › calcium metabolic disease › calcinosis › calciphylaxis

Related subtypes (2): nephrocalcinosis, familial tumoral calcinosis

Subtypes (2): calciphylaxis cutis, visceral calciphylaxis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE3	4
PHASE2	2
PHASE1	2
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT05018221	PHASE3	RECRUITING	Better Evidence and Translation for Calciphylaxis
NCT02527213	PHASE3	WITHDRAWN	Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy
NCT03150420	PHASE3	TERMINATED	A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients
NCT04195906	PHASE3	COMPLETED	Phase 3 Study of SNF472 for Calciphylaxis
NCT07583745	PHASE2	NOT_YET_RECRUITING	Study of EPN-701 for the Treatment of Calciphylaxis
NCT02790073	PHASE2	COMPLETED	Phase 2 Study With SNF472 in Calciphylaxis Patients
NCT01289626	PHASE1	COMPLETED	Efficacy of Lanthanum Carbonate in Calciphylaxis
NCT06283589	PHASE1	COMPLETED	The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
NCT04592640	EARLY_PHASE1	RECRUITING	Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
NCT02280733	Not specified	RECRUITING	A Real-World Registry of Chronic Wounds and Ulcers
NCT03032835	Not specified	RECRUITING	Partners Calciphylaxis Biobank
NCT06065852	Not specified	RECRUITING	National Registry of Rare Kidney Diseases
NCT07511283	Not specified	RECRUITING	Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)
NCT01578382	Not specified	COMPLETED	Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)
NCT02278692	Not specified	COMPLETED	Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
NCT02635373	Not specified	UNKNOWN	European Calciphylaxis Registry Network
NCT02854046	Not specified	COMPLETED	Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
NCT03146793	Not specified	UNKNOWN	The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort
NCT03319914	Not specified	TERMINATED	Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM THIOSULFATE	4	4
LANTHANUM CARBONATE	4	1
MAGNESIUM CITRATE	4	1
OXYGEN	4	1
PHYTONADIONE	4	1
VITAMIN K	4	1
HEXASODIUM PHYTATE	3	2
INZ-701	3	1
CHEMBL3753202	0	4